Coagulation & Bleeding Disorders — Coagulopathies, Anticoagulation, and Bleeding Management

The understanding of blood coagulation has evolved dramatically over centuries, transforming from rudimentary observations of clot formation to a sophisticated biochemical cascade model that underpins modern transfusion medicine, surgery, and pharmacotherapy. Early physicians recognized that blood could transition from a liquid to a solid state, but the mechanisms driving this phenomenon remained elusive until the twentieth century. The elucidation of coagulation pathways ultimately revolutionized how clinicians manage hemorrhagic disorders, prevent thromboembolic events, and perform invasive procedures safely. Understanding this history provides essential context for the rational use of anticoagulants, procoagulants, and reversal agents in contemporary clinical practice.

Despite these advances, clinicians continue to face fundamental challenges: How do you distinguish a platelet disorder from a coagulation factor deficiency at the bedside? When is anticoagulation indicated, and how do you manage life-threatening bleeding in an anticoagulated patient? These questions form the core of this lesson, bridging pathophysiology with evidence-based clinical management relevant to the USMLE Step 2 examination.

Normal hemostasis involves a tightly regulated sequence of events that arrests bleeding while preventing pathological thrombosis. A disruption at any point in this sequence can produce either a bleeding diathesis or a prothrombotic state. Clinically, understanding the distinction between primary hemostasis (platelet plug formation) and secondary hemostasis (coagulation cascade and fibrin stabilization) is essential for accurate diagnosis and targeted management. The fibrinolytic system then provides a counterbalancing mechanism to dissolve clots after tissue repair, and dysregulation of fibrinolysis can contribute to both bleeding and thrombosis.

The diagram above illustrates the classical cascade model, which remains clinically useful for interpreting laboratory assays. The prothrombin time (PT) and its standardized ratio (INR) reflect the function of the extrinsic and common pathways (factors VII, X, V, II, and fibrinogen), making them the primary monitoring tool for warfarin therapy. The activated partial thromboplastin time (aPTT) assesses the intrinsic and common pathways (factors XII, XI, IX, VIII, X, V, II, fibrinogen) and is used to monitor unfractionated heparin. When both PT and aPTT are prolonged, the defect lies in the common pathway or involves multiple factor deficiencies, as seen in disseminated intravascular coagulation (DIC) or severe liver disease.

Inherited Coagulopathies

Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are X-linked recessive disorders that present with deep tissue bleeding — hemarthroses, muscle hematomas, and prolonged bleeding after surgery or trauma. Laboratory findings reveal a prolonged aPTT with a normal PT. Severity correlates with residual factor activity: severe (<1%), moderate (1–5%), and mild (5–40%). Von Willebrand disease (vWD) is the most common inherited bleeding disorder, typically autosomal dominant, and presents with mucocutaneous bleeding because von Willebrand factor (vWF) mediates platelet adhesion and also carries factor VIII. Laboratory findings may show prolonged aPTT, prolonged bleeding time or abnormal PFA-100, and decreased vWF antigen and ristocetin cofactor activity.

Acquired Coagulopathies

Vitamin K deficiency impairs the hepatic synthesis of factors II, VII, IX, and X (as well as proteins C and S) because vitamin K is a required cofactor for the gamma-carboxylation of glutamic acid residues on these proteins. This produces a characteristic pattern of prolonged PT (first, since factor VII has the shortest half-life) followed by prolonged aPTT. Causes include malnutrition, biliary obstruction (fat-soluble vitamin malabsorption), prolonged antibiotic use (disruption of gut flora), and warfarin therapy.

Disseminated intravascular coagulation (DIC) is a consumptive coagulopathy triggered by systemic activation of the coagulation cascade, most commonly from sepsis, obstetric complications, malignancy, or major trauma. The pathophysiology involves simultaneous widespread microvascular thrombosis (leading to end-organ ischemia) and consumption of platelets and clotting factors (producing hemorrhage). Laboratory hallmarks include prolonged PT and aPTT, decreased fibrinogen, thrombocytopenia, elevated D-dimer, and schistocytes on peripheral smear. Treatment focuses on addressing the underlying cause while providing supportive transfusion therapy.

Liver disease impairs coagulation through multiple mechanisms: decreased synthesis of nearly all clotting factors (except factor VIII, produced by endothelial cells), decreased clearance of activated factors, thrombocytopenia (from splenic sequestration and decreased thrombopoietin), and dysfibrinogenemia. Unlike DIC, fibrinogen may be normal or elevated in early liver disease because it is an acute phase reactant, but it declines as hepatic synthetic function deteriorates.

Anticoagulant therapy is a cornerstone of managing thromboembolic disease, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, mechanical heart valves, and certain hypercoagulable states. Understanding the mechanism of action, monitoring parameters, and reversal strategies for each agent is critical for USMLE Step 2 and for safe clinical practice.

Key Pharmacological Considerations

Warfarin inhibits vitamin K epoxide reductase (VKORC1), preventing the regeneration of reduced vitamin K needed for gamma-carboxylation of factors II, VII, IX, and X. Because it also inhibits proteins C and S (natural anticoagulants with shorter half-lives), initiation of warfarin without heparin bridging can paradoxically produce a transient prothrombotic state, occasionally manifesting as warfarin-induced skin necrosis. The target INR for most indications is 2.0–3.0, with a higher range (2.5–3.5) for mechanical mitral valves. Warfarin's effect is influenced by dietary vitamin K intake, hepatic function, and numerous drug interactions mediated by the cytochrome P450 system (particularly CYP2C9).

Unfractionated heparin (UFH) binds antithrombin III, catalyzing its inhibition of thrombin (factor IIa) and factor Xa approximately 1,000-fold. It is monitored by the aPTT (target typically 1.5–2.5 × control) or anti-Xa levels, and is fully reversible with protamine sulfate. Its short half-life and titrability make it ideal for perioperative anticoagulation and situations where rapid reversal may be needed.

Direct oral anticoagulants (DOACs) have largely replaced warfarin for non-valvular atrial fibrillation and VTE treatment. Dabigatran is a direct thrombin inhibitor reversed by idarucizumab. Rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors; andexanet alfa is the specific reversal agent for Xa inhibitors. Advantages over warfarin include predictable pharmacokinetics, no routine monitoring, fewer food and drug interactions, and rapid onset of action. However, DOACs are contraindicated with mechanical heart valves and require renal dose adjustments (particularly dabigatran, which is 80% renally cleared).

A 72-year-old woman on warfarin for atrial fibrillation presents to the emergency department with melena and hematemesis. Her vitals show HR 112, BP 88/54. Labs reveal: INR 8.2, hemoglobin 6.8 g/dL, platelets 185,000/μL. Walk through the clinical management step by step.

Understanding coagulopathies at the Step 2 level provides a foundation for more complex clinical scenarios encountered in critical care, hematology consultations, and Step 3 content. Several advanced topics directly build upon the principles discussed in this lesson.

The cell-based model of coagulation, emphasizing the roles of tissue factor-bearing cells and activated platelets across three overlapping phases (initiation, amplification, propagation), is increasingly favored over the classical cascade model for explaining in vivo hemostasis. While the cascade model remains essential for interpreting PT and aPTT, understanding the cell-based model helps explain why patients with factor XII deficiency do not bleed (factor XII is dispensable in vivo) and why tissue factor pathway inhibitor (TFPI) plays a regulatory role that the classical model does not capture. Viscoelastic hemostatic assays like TEG and ROTEM reflect the entire process of clot formation, stabilization, and lysis in real time, providing information complementary to traditional coagulation tests.